Do analysts recommend PBYI or VRCA?

Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 159.39%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts recommend AVIR or VRCA?

Verrica Pharmaceuticals has a consensus target price of $14.50, indicating a potential upside of 159.39%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Verrica Pharmaceuticals (VRCA) Competitors

$5.59 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$5.40 -0.19 (-3.40%)

As of 07:32 AM Eastern

Compare

VRCA vs. PBYI, CMPX, UPB, PRLD, and AVIR

Should you buy Verrica Pharmaceuticals stock or one of its competitors? MarketBeat compares Verrica Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verrica Pharmaceuticals include Puma Biotechnology (PBYI), Compass Therapeutics (CMPX), Upstream Bio (UPB), Prelude Therapeutics (PRLD), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Verrica Pharmaceuticals compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Puma Biotechnology has a net margin of 10.69% compared to Verrica Pharmaceuticals' net margin of -47.97%. Puma Biotechnology's return on equity of 20.30% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Puma Biotechnology has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.90	$31.11M	$0.48	17.77
Verrica Pharmaceuticals	$35.58M	2.70	-$17.89M	-$1.03	N/A

In the previous week, Puma Biotechnology's average media sentiment score of 0.00 equaled Verrica Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Puma Biotechnology	Neutral
Verrica Pharmaceuticals	Neutral

Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 159.39%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Puma Biotechnology beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Verrica Pharmaceuticals presently has a consensus target price of $14.50, suggesting a potential upside of 159.39%. Compass Therapeutics has a consensus target price of $12.25, suggesting a potential upside of 497.56%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, Compass Therapeutics had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Compass Therapeutics and 0 mentions for Verrica Pharmaceuticals. Compass Therapeutics' average media sentiment score of 0.59 beat Verrica Pharmaceuticals' score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Compass Therapeutics	Positive

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Verrica Pharmaceuticals has higher revenue and earnings than Compass Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.70	-$17.89M	-$1.03	N/A
Compass Therapeutics	$850K	434.33	-$66.49M	-$0.41	N/A

Verrica Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Compass Therapeutics' return on equity of -39.75% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Compass Therapeutics	N/A	-39.75%	-35.29%

Summary

Compass Therapeutics beats Verrica Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Upstream Bio?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Verrica Pharmaceuticals presently has a consensus target price of $14.50, suggesting a potential upside of 159.39%. Upstream Bio has a consensus target price of $33.17, suggesting a potential upside of 373.13%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Verrica Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

In the previous week, Upstream Bio's average media sentiment score of 1.00 beat Verrica Pharmaceuticals' score of 0.00 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Upstream Bio	Positive

Verrica Pharmaceuticals has higher revenue and earnings than Upstream Bio. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.70	-$17.89M	-$1.03	N/A
Upstream Bio	$2.85M	133.85	-$143.44M	-$2.91	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 16.5% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Verrica Pharmaceuticals beats Upstream Bio on 8 of the 15 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Prelude Therapeutics?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

In the previous week, Prelude Therapeutics had 9 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 9 mentions for Prelude Therapeutics and 0 mentions for Verrica Pharmaceuticals. Prelude Therapeutics' average media sentiment score of 0.96 beat Verrica Pharmaceuticals' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Prelude Therapeutics	Positive

Verrica Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Verrica Pharmaceuticals currently has a consensus target price of $14.50, indicating a potential upside of 159.39%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 82.54%. Given Verrica Pharmaceuticals' higher probable upside, research analysts clearly believe Verrica Pharmaceuticals is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Verrica Pharmaceuticals has higher revenue and earnings than Prelude Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.70	-$17.89M	-$1.03	N/A
Prelude Therapeutics	$12.14M	27.55	-$99.50M	-$1.00	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Prelude Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Prelude Therapeutics' return on equity of -118.24% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Summary

Prelude Therapeutics beats Verrica Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Atea Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Atea Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Atea Pharmaceuticals' return on equity of -57.01% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Verrica Pharmaceuticals has a consensus target price of $14.50, indicating a potential upside of 159.39%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Atea Pharmaceuticals had 5 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 0 mentions for Verrica Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.42 beat Verrica Pharmaceuticals' score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Verrica Pharmaceuticals	Neutral

Verrica Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Verrica Pharmaceuticals	$35.58M	2.70	-$17.89M	-$1.03	N/A

Summary

Atea Pharmaceuticals and Verrica Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$96.04M	$3.04B	$6.86B	$12.27B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	-5.43	20.17	27.23	23.92
Price / Sales	2.70	803.37	577.77	113.62
Price / Cash	N/A	57.12	29.05	48.09
Price / Book	3.61	4.26	10.73	6.18
Net Income	-$17.89M	$65.46M	$3.59B	$331.89M
7 Day Performance	-5.57%	-1.44%	-1.02%	-1.28%
1 Month Performance	-0.71%	0.55%	1.66%	-1.36%
1 Year Performance	-31.52%	19.10%	25.63%	17.73%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	3.1141 of 5 stars	$5.59 flat	$14.50 +159.4%	-31.5%	$96.04M	$35.58M	N/A	40
PBYI Puma Biotechnology	1.0652 of 5 stars	$8.22 -0.5%	N/A	+150.9%	$418.40M	$228.40M	17.13	200	Positive News
CMPX Compass Therapeutics	2.5791 of 5 stars	$2.29 +0.9%	$12.25 +434.9%	-31.7%	$412.41M	$850K	N/A	20	Analyst Forecast
UPB Upstream Bio	2.2224 of 5 stars	$7.40 -1.5%	$33.17 +348.2%	-34.6%	$402.71M	$2.85M	N/A	38
PRLD Prelude Therapeutics	3.8406 of 5 stars	$4.99 +1.6%	$7.67 +53.6%	+421.7%	$397.43M	$16.72M	N/A	120	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. PBYI, CMPX, UPB, PRLD, and AVIR

How does Verrica Pharmaceuticals compare to Puma Biotechnology?

Summary

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Upstream Bio?

Summary

How does Verrica Pharmaceuticals compare to Prelude Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. PBYI, CMPX, UPB, PRLD, and AVIR

How does Verrica Pharmaceuticals compare to Puma Biotechnology?

Is PBYI or VRCA more profitable?

Do insiders and institutionals believe in PBYI or VRCA?

Which has more risk & volatility, PBYI or VRCA?

Which has higher earnings & valuation, PBYI or VRCA?

Does the media favor PBYI or VRCA?

Do analysts recommend PBYI or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Do analysts rate VRCA or CMPX?

Does the media refer more to VRCA or CMPX?

Do institutionals and insiders hold more shares of VRCA or CMPX?

Which has better valuation and earnings, VRCA or CMPX?

Which has more risk & volatility, VRCA or CMPX?

Is VRCA or CMPX more profitable?

Summary

How does Verrica Pharmaceuticals compare to Upstream Bio?

Do analysts rate VRCA or UPB?

Which has more risk & volatility, VRCA or UPB?

Is VRCA or UPB more profitable?

Does the media refer more to VRCA or UPB?

Which has better valuation and earnings, VRCA or UPB?

Do institutionals and insiders hold more shares of VRCA or UPB?

Summary

How does Verrica Pharmaceuticals compare to Prelude Therapeutics?

Does the media refer more to VRCA or PRLD?

Which has more risk and volatility, VRCA or PRLD?

Do analysts rate VRCA or PRLD?

Which has higher earnings and valuation, VRCA or PRLD?

Do institutionals & insiders have more ownership in VRCA or PRLD?

Is VRCA or PRLD more profitable?

Summary

How does Verrica Pharmaceuticals compare to Atea Pharmaceuticals?

Do insiders and institutionals have more ownership in AVIR or VRCA?

Which has more risk & volatility, AVIR or VRCA?

Is AVIR or VRCA more profitable?

Do analysts recommend AVIR or VRCA?

Does the media favor AVIR or VRCA?

Which has higher valuation & earnings, AVIR or VRCA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools